KEI Staff's blog

WHA70: Statement of Knowledge Ecology International on antimicrobial resistance

On Wednesday, 24 May 2017, Knowledge Ecology International delivered the following intervention on antimicrobial resistance. This statement was read by Andrew Goldman.

KEI would like to call attention to a proposal introduced in the United States Congress, as Senate Bill 771, sponsored by 16 US Senators, and HR 1776, which has 14 sponsors in the House of Representatives.


KEI Comments for 70th World Health Assembly Listening Session at DHHS

Today KEI attended the annual listening session at DHHS, when speakers are alotted no more than 1.5 minutes to speak on a specific agenda item, with no more than two agenda items per speaker. Our brief comments were focused on advancing the delinkage approach in the contexts of the GSPOA, CEWG, and cancer.

Experts, NGOs ask WHA delegates to support feasibility study of funding cancer research without high prices

On May 3, 2017, 29 civil society organizations and 33 health professionals, activists, and economists — including Nobel Prize laureate Joseph Stiglitz — asked delegates to the World Health Assembly (WHA) to support a feasibility study on the progressive delinkage of the costs of research and development from the price of cancer medicines. The groups and experts sent a letter to the delegates.

U.S. Army Rejects Pricing Concerns in Grant of Exclusive Patent License to Sanofi on Zika Vaccine

Today, KEI received a letter from the U.S. Army dated April 21, 2017, signed by Barry M. Datlof, in which the Army largely rejected concerns raised in comments submitted by KEI and various other public interest groups related to the proposed grant of an exclusive license to the French drug company Sanofi on a U.S. Army-invented vaccine for Zika virus.

KEI 10 March 2017 Comments on Army Exclusive License on Zika Virus Vaccine Patents to Sanofi

On March 10, 2017, KEI filed our 3rd set of comments with the U.S. Army Medical Research and Material Command (USAMRMC) on their proposed grant of an exclusive license on Zika virus vaccine patents to the French pharmaceutical company Sanofi.

KEI initial opposition to U.S. Army grant of exclusive license to Sanofi on patents for Zika virus vaccine

Building 810 December 21, 2016 -- KEI has filed comments with the U.S. Army Medical Research and Materiel Command (USAMRMC) on the proposed grant of an exclusive license to Sanofi on patents on a vaccine for Zika Virus.

Washington Monthly Cover Story Highlights Petition to Lower Price of Xtandi in U.S.


The November/December edition of the Washington Monthly cover story (available here) addresses executive actions to lower drug prices in the United States, in particular the use of march-in rights or royalty-free license rights in the Bayh-Dole Act. The story uses the case of Xtandi, a taxpayer-funded prostate cancer drug developed at UCLA with support from the National Institutes of Health and the U.S. Army, to highlight how those rights can be used by the executive branch to the lower the price of the drug. For more on Xtandi, see here:

WIPO General Assembly 2016: Opening Statement of Knowledge Ecology International

On October 4th, 2016, Knowledge Ecology International (KEI) delivered this opening statement on the occasion of the Fifty-Sixth Series of Meetings of the Assemblies of the Member States of the World Intellectual Property Organization (WIPO).

KEI General Statement - WIPO General Assembly - 2016

October 4th, 2016

Thank you Chair for providing Knowledge Ecology International (KEI) the opportunity to speak today.

KEI Statement on United Nations Secretary-General's High-Level Panel on Access to Medicines Report

On September 14, 2016, the United Nations Secretary-General's High-Level Panel on Access to Medicines issued its long-awaited report, which addressed the policy incoherencies between intellectual property, trade, human rights, innovation, and public health.

The report is available here:

NIH to taxpayers — we don't care about high prices in US for Xtandi.

National Institutes of Health Declines to Exercise Authority to Lower Xtandi Price
The National Institutes of Health will not use its rights under the Bayh-Dole Act to end the monopoly on the expensive prostate cancer drug Xtandi and allow low-priced generic versions to compete on the market.

Colombia Issues Public Interest Declaration To Lower Price of Glivec

Health Minister Alejandro Gaviria issued a declaration that it would be in the public interest for the government to lower the price of Novartis’ expensive leukemia drug, Gleevec (imatinib).

CONTACT: Andrew Goldman, +1 (202) 332-2670 or

The following individuals are also available for comment:

  • Andrea Carolina Reyes Rojas, Misión Salud:
  • Dr. Francisco Rossi, IFARMA:

Washington, DC, June 17, 2016 — Colombian Minister of Health Alejandro Gaviria today issued Resolution 2475 of 2016, declaring that it would be in the public interest for the government of Colombia to lower the price of an expensive leukemia drug. The Ministry of Health describes this resolution as unprecedented in Colombia.

The drug, imatinib, is marketed as Glivec in Colombia by the Swiss pharmaceutical company Novartis at a price of approximately $15,000 per patient per year, nearly twice the average income of a Colombian resident. Glivec has generated over $47 billion in global revenue for Novartis.

HAI/KEI intervention at the WHA69 on the negotiations on an R&D agreement

Jamie-740x.jpg The following is the intervention on behalf of Stichting Health Action International (HAI) at 69th World Health Assembly, Agenda Item 16.2: Follow-up to the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination - Report of the open-ended meeting of Member States.

KEI worked with HAI on the statement, and it was delivered by James Love

April 28, 2016 letter regarding US Senate Finance threats over compulsory license on Novartis cancer drug patents

Update: english translation of letter now available at end this blog.

April 27, 2016 Letter from Colombian Embassy regarding Senate Finance, USTR pressure on Novartis compulsory license

(More on Colombia here:

Updated to include English translation of letter. Note that KEI also has copy of the letter of April 28, 2016, reporting on the meeting with Eissenstat here.

Transparency of patents on medicines and other technologies

2016:1 KEI Briefing Note
Transparency of Patent Landscapes
April 25, 2016

At an April 12, 2016 WIPO seminar, Reed F. Beall and Amir Attaran presented a paper, “Patent-based Analysis of the World Health Organization’s 2013 Model List of Essential Medicines,” which includes the following odd comment:

Syndicate content